联邦制药研发的三重激动剂UBT251,在中国2型糖尿病患者中开展的二期临床试验取得积极结果。数据显示,经过24周的治疗后,患者糖化血红蛋白水平实现显著下降,平均降幅最高达到2.16%。该结果凸显了UBT251在血糖控制方面的潜在疗效,为后续临床研究提供了有力支持。
联邦制药研发的三重激动剂UBT251,在中国2型糖尿病患者中开展的二期临床试验取得积极结果。数据显示,经过24周的治疗后,患者糖化血红蛋白水平实现显著下降,平均降幅最高达到2.16%。该结果凸显了UBT251在血糖控制方面的潜在疗效,为后续临床研究提供了有力支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.